We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical t... Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. Show more
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...
STARMAP (Study Treating Acquired Resistance: MAPK Amplifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and in combination with select targeted cancer...
Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.14 | -10.2333931777 | 11.14 | 11.84 | 8.53 | 111792 | 9.5705736 | CS |
4 | -2.62 | -20.7606973059 | 12.62 | 13.1 | 8.53 | 132795 | 10.86110396 | CS |
12 | -4.25 | -29.8245614035 | 14.25 | 15.2 | 8.53 | 205050 | 12.23187379 | CS |
26 | -4.25 | -29.8245614035 | 14.25 | 15.2 | 8.53 | 205050 | 12.23187379 | CS |
52 | -4.25 | -29.8245614035 | 14.25 | 15.2 | 8.53 | 205050 | 12.23187379 | CS |
156 | -4.25 | -29.8245614035 | 14.25 | 15.2 | 8.53 | 205050 | 12.23187379 | CS |
260 | -28.5 | -74.025974026 | 38.5 | 60 | 8.53 | 655414 | 46.19371076 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions